Ole Isacson

Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model.

Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh.

Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice.

Analysis of different promoter systems for efficient transgene expression in mouse embryonic stem cell lines.

A direct role of the homeodomain proteins Phox2a/2b in noradrenaline neurotransmitter identity determination.

Herpes simplex virus/adeno-associated virus hybrid vectors for gene transfer to neurons. Preparation and use.

Models of repair mechanisms for future treatment modalities of Parkinson's disease.

Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease.

Spatial memory testing decreases hippocampal amyloid precursor protein in young, but not aged, female rats.

Proteasome inhibition causes nigral degeneration with inclusion bodies in rats.

Regulation of dopamine cell type and transmitter function in fetal and stem cell transplantation for Parkinson's disease.

Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons.

Altered proteasomal function in sporadic Parkinson's disease.

Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome.

Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells.

Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner.

The production and use of cells as therapeutic agents in neurodegenerative diseases.

Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model.

Estrogen alters amyloid precursor protein as well as dendritic and cholinergic markers in a mouse model of Down syndrome.

Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation.

Problems and solutions for circuits and synapses in Parkinson's disease.

Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease.

Generalized brain and skin proteasome inhibition in Huntington's disease.

Region-specific cell grafting into cervical and lumbar spinal cord in rat: a qualitative and quantitative stereological study.

Intrastriatal transforming growth factor alpha delivery to a model of Parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons.

Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.

The homeodomain transcription factor Pitx3 facilitates differentiation of mouse embryonic stem cells into AHD2-expressing dopaminergic neurons.

Context-dependent neuronal differentiation and germ layer induction of Smad4-/- and Cripto-/- embryonic stem cells.

Netrin-1 and slit-2 regulate and direct neurite growth of ventral midbrain dopaminergic neurons.

Stem cells may reshape the prospect of Parkinson's disease therapy.

Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice.

Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease.

Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Long-term survival of dopamine neurons derived from parthenogenetic primate embryonic stem cells (cyno-1) after transplantation.

Insights into Parkinson's disease models and neurotoxicity using non-invasive imaging.

Stromal cell-derived inducing activity, Nurr1, and signaling molecules synergistically induce dopaminergic neurons from mouse embryonic stem cells.

Specific microRNAs modulate embryonic stem cell-derived neurogenesis.

Neural precursors derived from embryonic stem cells, but not those from fetal ventral mesencephalon, maintain the potential to differentiate into dopaminergic neurons after expansion in vitro.

Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation.

Axonal growth regulation of fetal and embryonic stem cell-derived dopaminergic neurons by Netrin-1 and Slits.

Neuroblast protuberances in the subventricular zone of the regenerative MRL/MpJ mouse.

What are the long-term effects of neural grafting in patients with Huntington's disease?

Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin.

Transplanted dopamine neurons derived from primate ES cells preferentially innervate DARPP-32 striatal progenitors within the graft.

Selection of embryonic stem cell-derived enhanced green fluorescent protein-positive dopamine neurons using the tyrosine hydroxylase promoter is confounded by reporter gene expression in immature cell populations.

Proteasome activator enhances survival of Huntington's disease neuronal model cells.

Inhibition of the dopamine D1 receptor signaling by PSD-95.

In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias.

Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations.

Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells.

Immature and neurally differentiated mouse embryonic stem cells do not express a functional Fas/Fas ligand system.

An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease.

Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models.

Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.

Cell therapy and stem cells in animal models of motor neuron disorders.

Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons.

Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease.

Recent advances in cell-based therapy for Parkinson disease.

Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease.

Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease.

Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years.

Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.

Fate mapping and lineage analyses demonstrate the production of a large number of striatal neuroblasts after transforming growth factor alpha and noggin striatal infusions into the dopamine-depleted striatum.

Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.

Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease.

ALS model glia can mediate toxicity to motor neurons derived from human embryonic stem cells.

Future of cell and gene therapies for Parkinson's disease.

Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics.

PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex.

Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors.

Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.

The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.

Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients.

CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells.

Molecular and cellular determinants for generating ES-cell derived dopamine neurons for cell therapy.

No evidence for disease-like processes in fetal transplants.

Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway.

Isolation and culture of ventral mesencephalic precursor cells and dopaminergic neurons from rodent brains.

Cell therapy ahead for Parkinson's disease.

Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.

High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life.

The transcription factor orthodenticle homeobox 2 influences axonal projections and vulnerability of midbrain dopaminergic neurons.

Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid.

The hAPP-YAC transgenic model has elevated UPS activity in the frontal cortex similar to Alzheimer's disease and Down's syndrome.

Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats.

Being too inclusive about synuclein inclusions.

Global gene expression profiling of somatic motor neuron populations with different vulnerability identify molecules and pathways of degeneration and protection.

The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration.

Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease.

Development of histocompatible primate-induced pluripotent stem cells for neural transplantation.

Oct4-induced reprogramming is required for adult brain neural stem cell differentiation into midbrain dopaminergic neurons.

Opportunities for neurorestorative therapies in PD using iPS and stem cells.

Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.

Using stem cells and iPS cells to discover new treatments for Parkinson's disease.

Clinical translation of stem cells in neurodegenerative disorders.

Viral and inflammatory triggers of neurodegenerative diseases.

α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits.

Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.

The search for genetic mouse models of prodromal Parkinson's disease.

Creation of an open-access, mutation-defined fibroblast resource for neurological disease research.

Stem cells for Parkinson's disease: advancing science but protecting patients.

Characterization and criteria of embryonic stem and induced pluripotent stem cells for a dopamine replacement therapy.

Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.

LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.

Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease.

Advances in stem-cell--generated transplantation therapy for Parkinson's disease.

Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95.

Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease.

Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection.

ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress.

Long-term health of dopaminergic neuron transplants in Parkinson's disease patients.

Successful Function of Autologous iPSC-Derived Dopamine Neurons following Transplantation in a Non-Human Primate Model of Parkinson's Disease.

A Nurr1 Agonist Causes Neuroprotection in a Parkinson's Disease Lesion Model Primed with the Toll-Like Receptor 3 dsRNA Inflammatory Stimulant Poly(I:C).

Sorting the wheat from the chaff in dopamine neuron-based cell therapies.